Loading...
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
Fulvestrant is recommended for patients with hormone receptor-positive (HR+) advanced breast cancer (ABC) who progress after aromatase inhibitor therapy. As most patients in this setting have already developed mechanisms of resistance to endocrine therapy, targeting biological pathways associated wi...
Saved in:
| Published in: | Target Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6407749/ https://ncbi.nlm.nih.gov/pubmed/30136059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-018-0587-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|